Lp(a) Medications and Clinical Trial Updates

If you have a high lipoprotein(a), or Lp(a), and were hoping a pill or injection could bring it down, we have bad news and good news.

Firstly, the bad news: no medication is currently approved specifically to lower Lp(a). The drug that was furthest along in testing, pelacarsen, missed its main goal in a large trial announced in September 2026.

There’s good news too, though: three other drugs are still being tested, and one would be the first pill option if it succeeds. And, if you do have high Lp(a), traditional treatments can help reduce other risk factors.

Below, we'll walk through what happened with the pelacarsen trial and what's still in the pipeline. We also cover what you can do about high Lp(a) while the research continues.

A Quick Recap: What Is Lp(a)?

Lp(a) is a cholesterol-carrying particle similar to LDL, the "bad" cholesterol most people have heard of. However, it has one extra part attached: a protein called apo(a). Apo(a) makes the particle more likely to contribute to artery plaque and blood clots.

Your Lp(a) level is set almost entirely by genetics, not diet or exercise. About one in five people worldwide has a high Lp(a) level.

Why Isn't There a Medication for High Lp(a) Yet?

Lp(a) has been a known risk factor for decades, but it's genuinely hard to target with a drug.

Cholesterol medications (like statins) work well on LDL but barely affect Lp(a). It took a newer generation of drug technology to make it possible to lower Lp(a) in the first place.

That newer technology works at the level of genetic instructions rather than the finished particle. Every cell follows instructions copied from your genes to build proteins, including the apo(a) hook. The newest drugs stop that copying step. This means that less apo(a) ends up in your blood.

This approach, sometimes called gene silencing, is new technology. That’s part of why it's taken this long for any Lp(a)-specific treatment to reach large trials at all.

Even once a drug can lower the number, that's only half the job. There also needs to be proof that it prevents heart attacks and strokes. Getting this proof requires large trials, following thousands of people for several years. Current drugs are still in this testing phase.

What Happened With Pelacarsen in September 2026?

Pelacarsen is a monthly injection designed to stop the liver from producing apo(a), the sticky tag that makes Lp(a) risky. In earlier, smaller trials, it lowered Lp(a) substantially.

On September 4, 2026, Novartis announced its Phase 3 results, from a trial called Lp(a)HORIZON. The trial enrolled 8,323 people with high Lp(a) and existing cardiovascular disease, making it one of the largest Lp(a) trials ever run. Pelacarsen lowered Lp(a) compared to placebo, exactly as intended. But even though it reduced Lp(a) on a blood test, it didn’t actually lead to a drop in cardiovascular death, heart attack, stroke, and urgent procedures for blocked arteries.

Let’s look at that in another way. A drug can successfully change a number on a blood test without that change actually preventing the health problem at hand. Lp(a) is what's sometimes called a marker — a stand-in that usually tracks with risk. But a separate trial needs to prove that changing the marker changes the outcome. That's what happened with pelacarsen.

The National Lipid Association stated that one negative trial doesn't undo the evidence that Lp(a) itself is a real, independent risk factor. They also pointed out that the trial didn’t mean lowering Lp(a) can never help. Three other trials, using different drugs and different mechanisms, are still running and could still succeed where pelacarsen fell short.

What Other Lp(a) Drugs Are Being Tested?

Three other drugs are currently in large, Phase 3 trials: olpasiran, lepodisiran, and muvalaplin.

Olpasiran

Olpasiran uses the same gene-silencing approach as pelacarsen, interrupting the liver's instructions for building apo(a). However, it’s a different medication made by a different company. It's specifically being tested in people who've already had a heart attack or similar event.

Because it works the same general way as pelacarsen, its outcomes trial, OCEAN(a)-Outcomes, is being watched closely. Some see it as a second test of whether this entire drug category can prevent heart attacks and strokes, not just whether one specific drug can.

Lepodisiran

Lepodisiran works through the same gene-silencing mechanism as olpasiran. It's meant to last longer in the body, requiring an injection only twice a year instead of every few months.

If it works, that longer spacing between doses could make it easier for people to stick to treatment.

Muvalaplin

Muvalaplin takes a completely different approach. Rather than stopping the liver from making apo(a) in the first place, it blocks the hook from attaching at all. This is meant to prevent the risky combined particle from forming.

It's also the only one of the three medications being tested as a pill rather than an injection, which would make it easier to take daily. In an earlier, smaller trial, the highest dose of muvalaplin lowered Lp(a) by roughly 86 percent after 12 weeks. However, that trial was measuring the drug's effect on Lp(a) levels themselves, not yet on heart attacks and strokes.

What Should You Do About High Lp(a) Right Now?

There's no approved Lp(a) medication today, but that doesn’t mean that your health is entirely out of your hands.

What you can do is be more aggressive about every other risk factor within your control. That means:

• Tighter management of LDL cholesterol
• Managing blood pressure and blood sugar
• Quitting smoking if you smoke
• Exercising regularly
• Eating a heart-healthy diet

None of these lower Lp(a) itself, but they reduce the total load on your arteries, which matters regardless of what your Lp(a) number is doing.

It's also important to know whether your Lp(a) has already contributed to plaque buildup. A blood test tells you your Lp(a) number, but it can't show you what's actually happening inside your arteries.

A calcium score is a low-cost scan that takes a few minutes and measures how much hard plaque is in your arteries. A CCTA costs more but goes deeper, showing soft plaque and hard plaque plus how much the arteries have narrowed.

Soft plaque can rupture and cause a heart attack, and even if it doesn’t, it can eventually harden. The good news is that it responds to treatment. Catching it early gives you and your doctor time to slow it down and help it stabilize. Seeing what's actually there turns a worry about a number into a clear plan.

The Bottom Line on Lp(a) Medications

There's still no approved medication for high Lp(a). The most advanced candidate, pelacarsen, missed its main goal in a large trial announced in September 2026.

But there’s hope. Three other drugs, working through different mechanisms and including the first potential pill option, are still being tested, with results years away.

Until there’s an approved medication, the most useful thing you can do is manage the risk factors you have some control over. It may also be helpful to have a coronary CT angiogram, which detects whether there’s actual plaque build-up in your arteries.